NICE gives Celgene's myeloma treatment the cold shoulder
- There is no cure for multiple myeloma, a form of blood caner.
- NICE asserts that there have been no clinical studies assessing the efficacy of Revlimid, compared with other treatments.
- Myeloma UK has expressed disappointment in NICE’s decision.
At the heart of NICE’s decision to reconsider its approval of Revlimid is the fear that it may not be the most cost-effective treatment option for multiple myeloma. In response to the decision, Eric Low, CEO of Myeloma UK said, “While there may be a lack of clinical trial evidence and uncertainty around its cost-effectiveness, there is no question about [Revlimid's] role in clinical practice in this setting. We strongly feel that it is now up to NICE and Celgene to come up with a solution and to make Revlimid available to the myeloma patients who need it, as a matter of urgency.”
- Pharma Times New NICE knockback for Celgene myeloma drug